Author:
Oliver Adam,Mossialos Elias,Robinson Ray
Abstract
In this article, we review the development of health technology assessment (HTA) in England and Wales, France, The Netherlands, and Sweden, and we summarize the reaction to these developments from a variety of different disciplinary and stakeholder perspectives (political science, sociology, economics, ethics, public health, general practice, clinical medicine, patients, and the pharmaceutical industry). We conclude that translating HTA into policy is a highly complex business and that, despite the growth of HTA over the past two decades, its influence on policy making, and its perceived relevance for people from a broad range of different perspectives, remains marginal.
Publisher
Cambridge University Press (CUP)
Reference15 articles.
1. New B .1996 The rationing agenda in the NHS.BMJ.312:1593–1601.
2. Henshall C , Oortwijn W , Stevens A , Granados A , Banta D .1997 Priority setting for health technology assessment. Theoretical considerations and practical approaches. Priority setting subgroup of the EUR-ASSESS project.Int J Technol Assess Health Care.13:144–185.
3. Bos M , Carlsson P , van der Kooij S, et al .1996 Technology assessment and coverage policy: The case of invasive cardiology therapy in five European countries.Barcelona:Catalan Agency for Health Technology Assessment.
4. Banta D , Oortwijn W. 2000 Health technology assessment and health care in the European Union.Int J Technol Assess Health Care.16:626–635.
5. Banta D , Behney C , Andrulis D. 1978 Assessing medical technologies.Bull N Y Acad Med.54:113–123.
Cited by
97 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献